• Kristy M Shaeer, Elizabeth M Sherman, Sami Shafiq, and Patrick Hardigan.
• J Am Pharm Assoc (2003). 2014 Nov 1; 54 (6): 610-7.

ObjectiveTo assess Florida pharmacists' experience, knowledge, and perception of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) and to identify areas for pharmacist training.DesignCross-sectional survey.SettingFlorida in March through July 2013.ParticipantsFlorida pharmacists.InterventionIn-person and online anonymous survey.Main Outcome MeasureFlorida pharmacists' experience, knowledge, and perceptions of PrEP.Results225 completed surveys were analyzed. Survey respondents were predominantly community pharmacists with mean age of 45.7 years and less than 20 years of experience. Only 22% of respondents reported dispensing PrEP to patients. Although 75% had completed HIV-related continuing education in the last 2 years, 63% were unaware of Centers for Disease Control and Prevention PrEP guidelines and 71% answered that they did not have sufficient knowledge to counsel patients with PrEP prescriptions. Importantly, 47% of respondents answered they were uncomfortable counseling patients about PrEP. By self-report, most pharmacists agreed PrEP leads to risky behavior (68%) and increased rates of sexually transmitted infections (65%), and is too costly to promote patient access (92%).ConclusionSurveyed Florida pharmacists reported limited understanding of PrEP. As a widely accessible health care counseling resource, pharmacists are positioned to improve patient understanding, promote medication adherence, and enhance PrEP efficacy. Especially during PrEP implementation, when patients may receive PrEP prescriptions from non-HIV specialist prescribers, improving pharmacists' PrEP education presents a salient opportunity.

34 keywords...

hide…